This protocol was undertaken to determine if Sandoglobulin can be infused rapidly in an outpatient setting similar to a physician's office and to determine the maximum flow rates of Sandoglobulin which may be safely infused in subjects with primary immunodeficiency diseases without inducing undesirable side effects.
Showing the most recent 10 out of 336 publications